May 27, 2021
A member of the Judicial Panel on Multidistrict Litigation on Thursday questioned Mallinckrodt ARD LLC's push to have a battery of antitrust cases over sales of the anti-seizure drug Acthar transferred to federal court in Delaware where the company is currently making its way through bankruptcy proceedings.
January 28, 2021
Mallinckrodt has urged federal courts around the country to transfer cases involving the drugmaker's hormone treatment Acthar that make claims for antitrust, racketeering and other violations to the Delaware court overseeing its bankruptcy.
August 14, 2020
Mallinckrodt Ard LLC must face claims by Humana Inc. that it ran a scheme to keep a competitor to its infant spasm drug off the market after a California federal judge on Friday allowed the bulk of the claims in the suit to go forward.
May 26, 2020
Mallinckrodt has asked a California federal judge to cut more antitrust claims from Humana's $700 million price-gouging lawsuit over an infant seizure syndrome treatment, claiming the insurer yet again defined the market too narrowly.
March 11, 2020
A California federal judge has cut antitrust claims from Humana's suit accusing Mallinckrodt of orchestrating an "outrageous" price-gouging scheme for a hormone gel after finding problems with how the insurer defined the market, but left racketeering and state law claims intact.
October 29, 2019
Mallinckrodt has urged a California federal judge to toss Humana's $700 million price-gouging lawsuit over an infant seizure syndrome treatment, arguing that the insurer cannot rely on settlements with federal antitrust enforcers to get around the fact that massive price increases were required to keep the therapy in production.
August 09, 2019
Mallinckrodt ran "one of the most outrageous price-gouging schemes in the history of American medicine" on its hormone gel used primarily to treat an infant seizure syndrome, according to a new suit filed by Humana, which says the scheme has cost it more than $700 million.